New Strategies and Clinical Translation Progress in Immunotherapy for Liver Cancer

6,320
Total downloads
47k
Total views and downloads

Articles

CASE REPORT

Published on 05 Aug 2026

Metachronous severe multisystem immune-related adverse events during tremelimumab plus durvalumab therapy for hepatocellular carcinoma: a clinicopathological autopsy case report

Takuto Nosaka
Junki Yamashita
Yu Akazawa
Tomoko Tanaka
Kazuto Takahashi
Tatsushi Naito
Masahiro Ohtani
Yukihiro Kimura
Yoshiaki Imamura
2 more
Yasunari Nakamoto

doi 10.3389/fonc.2026.1830325

221 views

ORIGINAL RESEARCH

Published on 30 Jul 2026

Efficacy analysis of icaritin combined with transarterial chemoembolization in hepatocellular carcinoma stratified by different child-pugh classes

Jingxuan Xu
Yao Xing
Fenhua Zhao
Bufu Tang
Xinghai Li
Jiangping Cun
Huilin Lu
Xiangwen Xia
Hongjie Fan
1 more
Tao Xu

doi 10.3389/fimmu.2026.1876151

317 views

ORIGINAL RESEARCH

Published on 30 Jun 2026

Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis

Rui Feng
Liman Huo
Yun-Feng Diao
Yajing Wang
Mei Zhou
Ying Zheng
Qi Lv

doi 10.3389/fphar.2026.1860312

978 views

ORIGINAL RESEARCH

Published on 29 Jun 2026

Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization versus lenvatinib plus tislelizumab in patients with BCLC stage 0 -B hepatocellular carcinoma after radical resection

Xu Feng
Yupei Ao
Lili Wang
Kai Chen
Chengjia Tang
Chengcheng Huang

doi 10.3389/fimmu.2026.1778330

926 views

SYSTEMATIC REVIEW

Published on 25 May 2026

The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to transarterial chemoembolisation for unresectable, non-metastatic hepatocellular carcinoma: a pooled analysis of four RCTs

Tonggang Zhou
Chunlin Yu
Baoliang Zhong
Linqing Wang
Xiaoqing Zeng
Yan Wang

doi 10.3389/fmed.2026.1792746

1,352 views

ORIGINAL RESEARCH

Published on 23 Apr 2026

Efficacy of immunotherapy and targeted therapy for unresectable hepatocellular carcinoma: analysis of survival curves

Wan Zhou
Pan Xu

doi 10.3389/fmed.2026.1774216

1,203 views

ORIGINAL RESEARCH

Published on 23 Apr 2026

The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma

Hesheng Lin
Xueyao Wang
Jianhong Zhong
Ning Peng
Shaoping Liu
Fanjian Zeng
Wenfeng Li
Ze Su
Junjie Ou
2 more
Shuqun Li

doi 10.3389/fimmu.2026.1802427

1,061 views

REVIEW

Published on 13 Apr 2026

Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies

Zhenxao Wang
Jun Wu
Qiao Li
Xin Wen

doi 10.3389/fimmu.2026.1804366

1,747 views

ORIGINAL RESEARCH

Published on 10 Apr 2026

Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study

Li-Wei Deng
Jun-Feng Liu
Hai-Yan Yu
Bo Peng
Bin Liu
Shi-Feng Feng
Dong-Xu Liu
Yan-Yuan Sun
Yan Chen
9 more
Xue-Gang Yang

doi 10.3389/fimmu.2026.1748142

1,070 views

STUDY PROTOCOL

Published on 31 Mar 2026

Exploring the optimal regimen in advanced hepatocellular carcinoma: a protocol of individual patient data network meta-analysis of randomized controlled trials

Jiefeng Luo
Zhengxiong Li
Jun Ge
Sizhen Cai
Xinyi Mo
Wensheng Liu
Chengxia Gui
Qiong Du

doi 10.3389/fimmu.2026.1804661

1,590 views

ORIGINAL RESEARCH

Published on 27 Mar 2026

Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma

Yong Cui
Lijun Wang
Xiaoting Li
Kun Wang
Hongwei Wang
Quan Bao
Haitao Zhu
Xiaolei Gu
Qian Xing
2 more
Baocai Xing

doi 10.3389/fimmu.2026.1782008

1,124 views

ORIGINAL RESEARCH

Published on 09 Mar 2026

Outcomes of transarterial chemoembolization plus percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma with tumor diameter > 3 cm versus ≤ 3 cm: a single-center retrospective study

Yong Xie
Tianshi Lyu
Haitao Guan
Li Song
Yinghua Zou
Jian Wang

doi 10.3389/fonc.2026.1727692

1,135 views

Share on

Frontiers in Medicine

Hepatobiliary Diseases

Other participating journals

Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- 7.0 impact factor
- 11.3 citescore
Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- 3.4 impact factor
- 6.6 citescore

Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.

Impact

47kTopic views
37kArticle views
6,320Article downloads

View impact

Articles

Metachronous severe multisystem immune-related adverse events during tremelimumab plus durvalumab therapy for hepatocellular carcinoma: a clinicopathological autopsy case report

Efficacy analysis of icaritin combined with transarterial chemoembolization in hepatocellular carcinoma stratified by different child-pugh classes

Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis

Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization versus lenvatinib plus tislelizumab in patients with BCLC stage 0 -B hepatocellular carcinoma after radical resection

The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to transarterial chemoembolisation for unresectable, non-metastatic hepatocellular carcinoma: a pooled analysis of four RCTs

Efficacy of immunotherapy and targeted therapy for unresectable hepatocellular carcinoma: analysis of survival curves

The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma

Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategies

Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study

Exploring the optimal regimen in advanced hepatocellular carcinoma: a protocol of individual patient data network meta-analysis of randomized controlled trials

Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma

Outcomes of transarterial chemoembolization plus percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma with tumor diameter > 3 cm versus ≤ 3 cm: a single-center retrospective study

Frontiers in Medicine

Hepatobiliary Diseases

Other participating journals

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Frontiers in Oncology

Cancer Immunity and Immunotherapy